Desmoid Tumors — Microlearning Activity 1 with Dr Ravin Ratan

Dr Haley Ellis from Harvard Medical School in Boston, Massachusetts, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, Dr Zev Wainberg from UCLA School of Medicine in Los Angeles, California, and moderator Dr Lionel A Kankeu Fonkoua from Mayo Clinic in Rochester, Minnesota, discuss recent data surrounding the management of HER2-positive GI cancers, alongside their perspectives on its clinical application and management.CME information and select publications here.

Dr Ravin Ratan from The University of Texas MD Anderson Cancer Center in Houston discusses available clinical data with treatment approaches for desmoid tumors, alongside clinical cases illustrating real-world application.CME information and select publications here.

Dr Haley Ellis from Mass General Brigham Cancer Institute in Boston, Massachusetts, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, Dr Zev Wainberg from UCLA Jonsson Comprehensive Cancer Center in Los Angeles, California, and moderator Dr Lionel A Kankeu Fonkoua from Mayo Clinic in Rochester, Minnesota, discuss recent data and provide their perspectives on the management of HER2-positive GI cancers.CME information and select publications here.

Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora, Colorado, discusses circulating tumor DNA-based molecular residual disease assessment and its current role in the management of colorectal cancer.NCPD information and select publications here.

Dr Stacey A Cohen from the University of Washington in Seattle, Dr Arvind Dasari from The University of Texas MD Anderson Cancer Center in Houston, and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora discuss the role of molecular residual disease assessment using circulating tumor DNA-based tools in the management of colorectal cancer.CME information and select publications here.

Dr Marwah Fakih from the City of Hope Comprehensive Cancer Center in Duarte, California, discusses current and potential therapeutic strategies for the treatment of squamous cell carcinoma of the anal canal.CME information and select publications here.

Dr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer.CME information and select publications here.

Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, Dr John Strickler from Duke University in Durham, North Carolina, and Dr Samuel Klempner from Massachusetts General Hospital in Boston review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.CME information and select publications here.

Dr Haley Ellis from Harvard Medical School in Boston, Massachusetts, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, Dr Zev Wainberg from UCLA School of Medicine in Los Angeles, California, and moderator Dr Lionel KankeuFonkoua from Mayo Clinic in Rochester, Minnesota, discuss recent data surrounding the management of HER2-positive GI cancers, alongside their perspectives on its clinical application and management.CME information and select publications here.

Dr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston discusses recent developments with circulating tumor DNA assays in the management of colorectal cancer. CME information and select publications here.